CRISPR Therapeutics Reports 65% ANGPTL3 And 63% Triglyceride Reductions With CTX310 In Phase 1b Trial For Severe Hypertriglyceridemia; Well Tolerated, With No Treatment-Related Serious Adverse Events And No Clinically Relevant Elevations In Liver...

Benzinga
在Benzinga上打开